Zurzuvae

Zurzuvae is a 14-day oral pill for adults with postpartum depression, offering rapid improvement in depressive symptoms. It helps new mothers regain mood balance after childbirth.

Molecule Details :

  • Molecule Name :

    Zuranolone
  • Innovator :

    BIOGEN INC
  • Approval Date :

    04-Aug-23
  • NCE-1 Date :

    04-Aug-27
  • NCE Date :

    04-Aug-28
  • Dosage Form :

    Capsule
  • Strength :

    20mg, 25mg and 30mg
  • Therapeutic Category :

    Antidepressant
  • Revenue ($M) :

    72

Year-wise Projected Sales ($M) :

  • 2025 :

    232
  • 2026 :

    352
  • 2027 :

    487
  • 2028 :

    600
  • 2029 :

    693
  • 2030 :

    775
  • 2031 :

    838
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?